Merck & Co., Inc. vs Xpeng Inc - ADR — how do they compare? Merck & Co., Inc. trades at $126.14 (market cap $307.25B), while Xpeng Inc - ADR trades at $13.35 (market cap $12.96B). The key difference: Merck & Co., Inc. is far larger — about 23.7× Xpeng Inc - ADR's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| MRK | XPEV | |
|---|---|---|
Market Cap | $307.25B | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.52 | $28.07 |
52-Week Low | $77.60 | $12.09 |
Enterprise Value | $350.66B | $15.07B |
Dividend Yield | 2.73% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →